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Abstract 
There are very limited data on ticarcillin-clavulanate elimination by haemofiltration. We 
measured in vitro ticarcillin-clavulanate adsorption to polyacrylonitrile filters and the sieving 
coefficient, using a well-described bench model of haemofiltration. The dose of ticarcillin-
clavulate was 60/2 mg or 180/3 mg and 0 or 12 g albumin was added to the 1 l of circulating 
blood-crystalloid mixture to produce 4 different experimental conditions. The experiment was 
repeated four times under each condition. Median (IQR) ticarcillin adsorption varied from 28 
(27-30) mg to 85 (78-90) mg. Adsorption was increased when the dose of ticarcillin was 
higher (p<0.001), but was not affected by the addition of albumin. Median (IQR) adsorption 
of clavulanate ranged from 0.67 (0.55-0.75) mg to 1.8 (0.33-3.5) mg and was neither dose 
dependent (p=0.505) nor significantly affected by the addition of albumin. Median (IQR) 
ticarcillin sieving coefficient ranged from 0.73 (0.67-0.75) to 0.99 (0.97-1.03). It was 
significantly higher with a higher dose of ticarcillin (p=0.021) and without addition of 
albumin (p=0.015). Median (IQR) clavulanate sieving coefficient ranged from 1.03 (1.00-
2.24) to 2.0 (1.98-2.47). Clavulanate sieving coefficient was not significantly affected by dose 
or the addition of albumin. 
 
These data suggest that significant adsorption of both ticarcillin and clavulanate occurs in 
vitro, however this requires confirmation by clinical pharmacokinetic studies. The sieving 
coefficient data may help guide appropriate dosing of critically ill patients receiving 
haemofiltration until more extensive clinical pharmacokinetic data are available. 
 
Keywords: clavulanic acid; ticarcillin; renal replacement therapy; critical illness; 
pharmacokinetics. 
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PAN: polyacrylonitrile 
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Introduction 
Ticarcillin-clavulanate is an intravenous anti-bacterial agent which consists of a beta-lactam, 
ticarcillin disodium, and beta-lactamase inhibitor, clavulanate potassium. Approximately 60% 
to 70% of ticarcillin and 35% to 45% of clavulanic acid are excreted unchanged in urine 
during the first 6 hours after administration of a single dose of ticarcillin-clavulanate in a 
normal individual with normal renal function. Dosage adjustment is recommended in severe 
renal failure [1]. At high serum concentrations ticarcillin is known to cause neurotoxicity, 
including seizures and changes in mental state [2]. Although ticarcillin can be removed by 
intermittent dialysis [1, 3,4]renal replacement therapy in critically ill patients is commonly in 
the form of continuous therapy such as haemofiltration rather than intermittent dialysis [5] 
and data on elimination of ticarcillin-clavulanate by haemofiltration are limited to a single 
study in three children [6,7]. 
 
There is considerable variability in the application of haemofiltration in critically ill patients. 
In particular, changes in effluent rate may result in marked changes in clearance [6]. As a 
result it may be more useful to measure sieving coefficient and calculate clearance from 
effluent rate, sieving coefficient and blood flow rate [6]. However, this does not take into 
account elimination that may occur as a result of adsorption to the haemofilter or the 
extracorporeal circuit. In vitro data suggests that this may be important for some [8,9] but not 
all [10,11] antibiotics. Greater adsorption appears to occur to polyacrylonitrile haemofilters 
than filters that use a different material [12]. 
 
We therefore carried out an in-vitro study to measure adsorption of ticarcillin and clavulanate 
to polyacrylonitrile haemofilters and the sieving coefficient of both drugs, using a previously 
published methodology [12]. 
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Material and Methods 
The study consisted of two parts. The first was designed to measure adsorption and the second 
to measure sieving coefficient. 
 
Both parts used a previously described bench model of haemofiltration [12]. This consisted of 
a reservoir of a blood-crystalloid mixture to which ticarcillin-clavulanate was added. This 
mixture was then pumped through a standard haemofiltration circuit with a 0.6m
2
 
polyacrylonitrile (PAN) haemofilter (Multiflow 60; Hospal, Meyzieu, France) at a rate of 200 
ml/min. Ultrafiltrate was removed at a rate of 1000 ml/hr. In the first part the ultrafiltrate was 
returned to the reservoir creating a closed system from which drugs could only be eliminated 
by adsorption. In the second part ultrafiltrate was replaced by a bicarbonate buffered 
replacement solution (Haemosol BO, Gambro Dasco S.p.A, Sondalo, Italy). The blood-
crystalloid mixture consisted of 1 unit of expired packed red blood cells, with and without 12 
g of albumin made up to a total volume of 780 ml with heparinarized lactated Ringer’s 
solution (5000 unit heparin/L). The haemofilter and circuit were primed with 220 ml 0.9% 
saline to make a total circulating volume of 1000 ml. 
 
Ticarcillin-clavulanate doses were chosen to reflect clinically relevant concentrations [13]. 
The doses used in our study were 60 mg and 180 mg of ticarcillin equivalent, resulting in 
ticarcillin concentrations of 60 mg/l and 180 mg/l and clavulanate concentrations of 2 mg/l 
and 6 mg/l. The experiment was carried out four times under four different conditions: 60 
mg/2 mg ticarcillin/clavulanate without added albumin; 60 mg/2 mg ticarcillin/clavulanate 
with added albumin; 180 mg/6 mg ticarcillin/clavulanate without added albumin and 180 
mg/6 mg ticarcillin/clavulanate with added albumin. 
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During the first part of the study, blood samples were taken from the reservoir immediately 
before adding ticarcillin-clavulanate and then 20, 50 and 80 minutes later. Adsorption was 
estimated by subtracting the measured concentration of ticarcillin and clavulate from the 
original dosed concentration and converting this to an amount.  
 
The second part of the study consisted of six 15-minutes periods between which the point of 
dilution was alternated between pre-dilution and post-dilution. Each 15-minute period 
consisted of a 9-minute equilibration and then 6-minute sampling period when the ultrafiltrate 
was collected. Blood samples were taken from the filter inlet and filter outlet 3 minutes after 
the beginning of sampling period. 
Sieving coefficient was calculated from: 
 
Sieving coefficient = (2 x [Drug]u) / ([Drug]a + [Drug]v) [6] 
 
Where [Drug]u is the ultrafiltrate drug concentration, [Drug]a is the filter inlet drug 
concentration and [Drug]v is the filter outlet concentration 
 
Blood samples were centrifuged immediately after sampling. The serum and ultrafiltrate 
samples were stored at -80°C until assayed. 
 
Ticarcillin and clavulanate in plasma were measured by a validated Liquid Chromatography-
Mass Spectrometry method using a Nexera2 UHPLC system coupled to a 8030+ triple 
quadrupole mass spectrometer (Shimadzu, Kyoto, Japan). The linear range when assaying 
ticarcillin was 1 to 200 mg/L with intra-batch accuracy of 11.2, 0.3 and 1.0% and precision of 
2.6, 10.6 and 0.9% at 3, 30 and 150 mg/L respectively. The linear range when assaying 
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clavulanate in plasma was 0.33 to 6.67 mg/L with intra-batch accuracy of 1.4 and 2.3 % and 
precision of 14.3 and 3.6% at 1 and 5 mg/L, respectively. 
Ticarcillin and clavulanate concentrations in ultrafiltrate were determined by a validated high 
performance liquid chromatography method with ultraviolet detection on a Nexera-PDA 
instrument (Shimadzu, Kyoto, Japan). Ticarcillin was measured in ultrafiltrate from 1 to 200 
mg/L with intra-batch accuracy of 2.3, 1.3 and 0.9% and a precision of 0.1, 0.1 and 0.2% at 6, 
30 and 150 mg/L. Clavulanate in ultrafiltrate was measured from 0.167 to 6.67 mg/L with 
intra-batch accuracy of 19.1, 5.5 and 2.4% and a precision of 6.2, 0.6 and 0.1% at 0.2, 1 and 5 
mg/L.The effect of dose and the addition of albumin on adsorption was analyzed using the 
Mann-Whitney U test. 
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Results 
The magnitude of adsorption to the filter and sieving coefficients in the different experimental 
settings are given in table 1.  
 
Absolute ticarcillin adsorption was increased when the dose of ticarcillin was higher 
(p<0.001), but clavulanate adsorption was not dose dependent (p=0.505). Neither ticarcillin 
adsorption (p=0.645) nor clavulanate adsorption (p=0.721) were significantly affected by the 
addition of albumin. The time course of adsorption was rapid, with little additional adsorption 
occurring after 20 minutes (figure 1). 
 
Ticarcillin sieving coefficient was significantly higher with a higher dose of ticarcillin 
(p=0.021) and without addition of albumin to the blood-crystalloid mixture (p=0.015). 
Clavulanate sieving coefficient was not significantly affected by dose (p=0.867) or the 
addition of albumin (p=0.867). 
 
Clavulanate was rapidly eliminated with concentrations falling below the lower limit of 
quantification within a few 15 minute cycles. This precluded any meaningful investigation of 
the effect of pre and post dilution on sieving coefficient. The sieving data presented represent 
the mean sieving coefficient for each filter used, regardless of pre or post dilution. 
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Discussion 
Substantial adsorption of ticarcillin appears to occur with approximately 46-48% of the dose 
being adsorbed within 20 minutes of administration. Proportionally less clavulanate was 
adsorbed (23-33%). Our data indicate a sieving coefficient of 0.73-0.99 for ticarcillin and 
1.03-2.0 for clavulanate. 
 
Although ticarcillin, and to a lesser extent, clavulanate were adsorbed to the haemofilter 
and/or circuit, this finding should be interpreted with caution. We have previously shown in 
vitro of adsorption meropenem, piperacillin [14] and vancomycin [11] and very substantial in 
vitro adsorption of aminoglycosides [8,9] but, in a porcine model of acute renal failure, 
adsorption had only a small effect on peak amikacin concentrations [15]. Nevertheless, further 
investigation of the adsorption of ticarcillin and clavulanate is warranted. Where it is 
available, therapeutic drug monitoring would help to confirm or refute the need for additional 
dosing to adjust for elimination for any adsorption that may occur in vivo. 
 
The data on sieving coefficient are similar to those in the only published clinical study of 
ticarcillin-clavulanate clearance by haemofiltration [16], which found a ticarcillin sieving 
coefficient of 0.61-1.06 and clavulanate sieving coefficient of 1.44-1.97 in three children 
receiving continuous venovenous haemofiltration in pre-dilution mode using a 0.25 m
2
 
polysulphone filter. Two were also receiving extracorporeal membrane oxygenation. The 
mechanism underlying the very high sieving coefficient for clavulanate is unclear. Typically 
antibiotics have a sieving coefficient that ranges between 0 and 1 with a sieving coefficient 
that is related to the unbound fraction [6]. However, protein binding clearly cannot explain a 
sieving coefficient >1. Clavulanate is an anion and thus its sieving coefficient may be 
increased by the Gibbs-Donnan effect [6]. This effect occurs as a result of the retention of 
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anionic protein on the blood side of the filter membrane leading to retention of cations and 
increased elimination of anions. However, the clinical relevance of the Gibbs-Donnan effect 
is unclear. The negative charge of PAN filters may have enhanced the Gibbs-Donnan effect in 
our experiment but it should be noted that the high sieving coefficients reported in clinical 
practice [16] occurred in children being filtered using polysulfone haemofilters which have no 
charge. 
 
By using the sieving coefficient and the effluent rate it is possible to calculate the clearance 
by haemofiltration and hence make an appropriate dose adjustment in patients receiving 
haemofiltration [6]. As the sieving coefficient for clavulanate is substantially higher than for 
ticarcillin, at any given effluent rate, clearance of clavulanate will be substantially higher than 
ticarcillin. This raises the question of whether additional doses of clavulanate (without 
ticarcillin) need to be given. Our data cannot answer that question as the pharmacokinetic-
pharmacodynamic relationship for clavulanate is poorly understood. However, our data do 
indicate a need for further investigation of this issue. Similar considerations are likely to 
apply to dosing of amoxycillin-clavulanate but there are no data on the pharmacokinetics of 
this agent in patients receiving continuous renal replacement therapy.  
 
Our study has a number of limitations. First and foremost, it utilized a single compartment 
bench model. As noted above this may overestimate the extent of adsorption in vivo. Limited 
data on other antimicrobials suggests that in vitro sieving coefficients are similar to in vivo 
coefficients in most [12,14,17,18] but not all cases [19]. The sieving coefficients for ticarcillin 
and clavulanate obtained in this study are similar to those seen in the three patients that have 
been studied, albeit using haemofilters made from a different material. However, although 
previous studies using the same experimental model confirmed that the circulating fluid is 
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hypoalbuminaemic [8], as are most critically ill patients, the model does not take into account 
possible binding to acute phase proteins, that are elevated in critical illness. Secondly, we 
were unable to assess the effect of dilution mode. Our previous experiment with levofloxacin 
showed only a minor decrease in sieving coefficient when post dilution was used compared to 
pre-dilution [12], although a large effect was shown in vivo for vancomycin [20]. Thirdly, we 
only studied PAN haemofilters. Sieving coefficients were similar when polysulfone filters 
were used in vivo but it is possible that different results might be obtained with other 
commonly used filter membranes such as polyethersulphone or polyamide[10,11,12]. Finally, 
we are unable to categorically exclude the possibility of sampling or measurement error as a 
cause for a clavulanate sieving coefficient >1, for example greater instability of clavulanate in 
stored plasma compared to ultrafiltrate specimens. However, our data are similar to the only 
other data on clavulanate sieving coefficient and clavulanate rapidly became undetectable in 
the circulating blood-crystalloid mixture suggesting a high clearance. As clearance is mainly 
dependent on sieving coefficient and effluent rate, we believe the high sieving coefficient was 
not due to error. 
 
In conclusion, our data confirm previous, extremely limited, clinical data regarding the 
sieving coefficient for ticarcillin (0.73-0.99) and the extremely high sieving coefficient for 
clavulanate (1.03-2.0). The clinical significance of the high clavulanate sieving coefficient is 
unclear but it may indicate the need to evaluate whether additional doses of clavulanate alone, 
in the clinical setting, are warranted. Similar considerations may also apply to amoxycillin-
clavulanate. The limitations of our experimental model mean that our in vitro sieving 
coefficients should only be used to aid dosing until further research establishes in vivo 
coefficients, and only when using PAN haemofilters While we would not currently 
recommend clinical dose adjustment based on the in vitro adsorption data alone, the data on 
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adsorption indicate that further investigation of ticarcillin and clavulanate adsorption are 
warranted.  
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Figure 1. Median adsorption of ticarcillin and clavulanate against time. Squares represent 
high dose (180 mg ticarcillin, 6 mg clavulanate), circles low dose (60 mg ticarcillin, 2 mg 
clavulanate). Filled symbols and solid lines indicate added albumin (12 g) and unfilled 
symbols and dotted lines indicate absence of added albumin. Error bars show interquartile 
range. 
 
 
 
Table 1. Median (interquartile range) sieving concentration and adsorption by group.  
 
Ticarcillin/ 
clavulanate 
dose (mg) 
Added 
albumin 
(g) 
Ticarcillin sieving 
coefficient 
Clavulanate 
sieving 
coefficient 
Ticarcillin 
adsorption 
(mg) 
Clavulanate 
adsorption (mg) 
60/2 12 0.73 (0.67-0.75) 2.0 (1.57-2.79) 29 (28-30) 0.67 (0.55-0.75) 
180/6 12 0.85 (0.82-0.87) 1.9 (1.05-2.97) 85 (78-90) 1.8 (0.33-3.5) 
60/2 0 0.84 (0.81-0.88) 1.03 (1.00-2.24) 28 (27-30) 0.67 (0.53-0.88) 
180/6 0 0.99 (0.97-1.03) 2.0 (1.98-2.47) 81 (74-87) 0.96 (0.60-1.3) 
 
